-
Innovation Ranking
Innovation Ranking – Dynavax Technologies Corp
Dynavax Technologies Corp (Dynavax) is an biopharmaceutical company that develops novel vaccines based on Toll-like receptor(TLR) biology and also focuses on Various infectious and inflammatory diseases. The company marketed product Heplisav-B is an adult vaccine which is indicated for the prevention of hepatitis B. The company’s pipeline focuses on combining the innate immune response with other immunomodulatory agents for the treatment of cancer. Its ongoing studies include DV2-ZOS-01 for immune-mediated, herpes zoster, and anaphylaxis events; DV2-HBV-27 for the pregnancy registry....
-
Product Insights
NewAnthrax – Drugs In Development, 2024
Empower your strategies with our Anthrax – Drugs In Development, 2024 report and make more profitable business decisions. Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe bloody diarrhea in the later stages of the disease, sore throat, and difficulty swallowing. Risk factors include illegal intravenous drug use, exposure to animal skins, and working in veterinary medicine, especially dealing with livestock. The Anthrax drugs in development...
-
Product Insights
NewVaricella Zoster (HHV-3) Infections – Drugs In Development, 2024
Empower your strategies with our Varicella Zoster (HHV-3) Infections – Drugs In Development, 2024 report and make more profitable business decisions. Varicella-zoster virus (VZV), also known as human herpesvirus 3 (HHV-3), causes two distinct infections: chickenpox (varicella) and shingles (herpes zoster). Varicella is a highly contagious viral infection characterized by an itchy rash with red spots and fluid-filled blisters that break open and form scabs. It spreads through respiratory droplets and direct contact with the rash. Varicella commonly affects children, and...
-
Product Insights
NewSeasonal Influenza – Drugs In Development, 2024
Empower your strategies with our Seasonal Influenza – Drugs In Development, 2024 report and make more profitable business decisions. Seasonal influenza, commonly referred to as "the flu", is a contagious respiratory illness caused by influenza viruses. It typically occurs in outbreaks during the fall and winter months, peaking between December and February in the Northern Hemisphere. The flu can cause mild to severe illness and, in some cases, can lead to hospitalization or even death, especially among vulnerable populations. Symptoms of...
-
Product Insights
NewHerpes Zoster (Shingles) – Drugs In Development, 2024
Empower your strategies with our Herpes Zoster (Shingles) – Drugs In Development, 2024 report and make more profitable business decisions. Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain, and swollen glands. The predisposing factors include age and weakened immune system. Treatment includes antihistamines and pain relievers. The Herpes Zoster (Shingles) drugs in development market research report provide comprehensive information on the therapeutics under development...
-
Product Insights
NewNet Present Value Model: Dynavax Technologies Corp’s Z-1018
Empower your strategies with our Net Present Value Model: Dynavax Technologies Corp's Z-1018 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Z-1018 in Herpes Zoster (Shingles)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Z-1018 in Herpes Zoster (Shingles) Drug Details:Z-1018 is under development for the prevention of herpes zoster...
-
Company Insights
Innovation and Patenting activity of Dynavax Technologies Corp Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Dynavax Technologies Corp Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Profile
Dynavax Technologies Corp – Company Profile
Dynavax Technologies Corp (Dynavax) is an biopharmaceutical company that develops novel vaccines based on Toll-like receptor(TLR) biology and also focuses on Various infectious and inflammatory diseases. The company marketed product Heplisav-B is an adult vaccine which is indicated for the prevention of hepatitis B. It’s pipeline focuses on combining the innate immune response with other immunomodulatory agents for the treatment of cancer. Its ongoing studies include DV2-ZOS-01 for immune-mediated, herpes zoster, and anaphylaxis events; DV2-HBV-27 for the pregnancy registry. Dynavax...
Add to Basket -
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022
COVID-19 Analyst Consensus Sales Report Overview Prophylactic COVID-19 vaccines are projected to generate total sales of $264 billion from 2021 to 2028. The number of COVID-19 drugs with forecast sales nearly tripled due to the massive mandatory vaccination campaigns led by the major markets, which caused rapid increases in COVID-19 vaccines. BioNTech/Pfizer’s Comirnaty, Moderna’s Spikevax, and Pfizer’s Paxlovid are the top three marketed drugs with the highest peak forecast sales. Comparing Q4 2020 and H2 2022 total COVID-19 forecast sales within...